【Japan Lifeline】2026 Fiscal Year Financial Results｜Sales of 5.92 billion yen (YoY +4.6%)

Performance Overview

Japan Lifeline recorded sales of 5.92 billion yen (YoY +4.6%) and net income of 935 million yen ( +0.4%) for the fiscal year ending March 2026, reaching new record highs. Sales of medical devices remained robust, especially achieving double-digit growth in cardiovascular and cerebrovascular categories. The gross profit margin was 59.4%, and the operating profit margin was 21.3%, maintaining stable profitability. Despite an environment shaped by aging demographics and healthcare efficiency demands, the company continues to grow, addressing rising costs and pricing pressures through global expansion and new product development.

Outlook and Impact on Shareholders

For the fiscal year ending March 2027, the earnings forecast projects sales of 6.32 billion yen (+6.8%) and net income of 800 million yen (-14.4%), indicating a slight decline. However, core business growth is expected to continue, particularly in cerebrovascular and gastrointestinal fields, with double-digit growth anticipated. The dividend is planned to increase to 54 yen, reflecting a raise from the previous period, strengthening shareholder returns. The company will also focus on share buybacks and improving capital efficiency to enhance long-term corporate value.